31 – 45 of 47
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
Chronic intermittent L-DOPA treatment induces changes in dopamine release
(
- Contribution to journal › Article
-
Mark
Presynaptic mechanisms in L-DOPA-induced dyskinesia
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Gene therapy by enzyme replacement for Parkinson’s disease Optimization of continuous DOPA delivery and development of a candidate vector for clinical application
(
- Thesis › Doctoral thesis (compilation)
- 2008
-
Mark
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
(
- Contribution to journal › Article
- 2007
-
Mark
Expression pattern of JunD after acute or chronic l-DOPA treatment: Comparison with DeltaFosB.
(
- Contribution to journal › Article
-
Mark
Proteomic analysis of striatal proteins in the rat model of l-DOPA-induced dyskinesia.
(
- Contribution to journal › Article
-
Mark
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
(
- Contribution to journal › Article
- 2006
-
Mark
Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia.
(
- Contribution to journal › Article
-
Mark
Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.
(
- Contribution to journal › Article
- 2005
-
Mark
Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.
(
- Contribution to journal › Article
- 2004
-
Mark
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia
(
- Contribution to journal › Article
-
Mark
Modelling parkinsonian akinesia and dyskinesia in dopamine depleted rodents
2004)(
- Thesis › Doctoral thesis (compilation)
-
Mark
Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy)
(
- Contribution to journal › Article
- 2003
-
Mark
Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment.
(
- Contribution to journal › Article
-
Mark
Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.
(
- Contribution to journal › Article